We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > OT-58

News List

Retrophin Completes Acquisition of Orphan Technologies americanpharmaceuticalreview
November 25, 2020
Retrophin announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical ...
Retrophin to Acquire Orphan Technologies americanpharmaceuticalreview
October 26, 2020
Retrophin has entered into a definitive agreement to acquire Orphan Technologies, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU).